HK1216009A1 - 前列環素組合物及其使用方法 - Google Patents

前列環素組合物及其使用方法

Info

Publication number
HK1216009A1
HK1216009A1 HK16103948.9A HK16103948A HK1216009A1 HK 1216009 A1 HK1216009 A1 HK 1216009A1 HK 16103948 A HK16103948 A HK 16103948A HK 1216009 A1 HK1216009 A1 HK 1216009A1
Authority
HK
Hong Kong
Prior art keywords
prostacylin
compositions
methods
same
prostacylin compositions
Prior art date
Application number
HK16103948.9A
Other languages
English (en)
Inventor
Franziska Leifer
Donna M Omiatek
Jane Ong
Renu Gupta
Zhilli Li
Walter Perkins
Vladimir Malinin
Original Assignee
Insmed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Insmed Inc filed Critical Insmed Inc
Publication of HK1216009A1 publication Critical patent/HK1216009A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Otolaryngology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
HK16103948.9A 2012-11-30 2016-04-07 前列環素組合物及其使用方法 HK1216009A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261732223P 2012-11-30 2012-11-30
PCT/US2013/072647 WO2014085813A1 (en) 2012-11-30 2013-12-02 Prostacylin compositions and methods for using the same

Publications (1)

Publication Number Publication Date
HK1216009A1 true HK1216009A1 (zh) 2016-10-07

Family

ID=50828539

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16103948.9A HK1216009A1 (zh) 2012-11-30 2016-04-07 前列環素組合物及其使用方法

Country Status (12)

Country Link
US (1) US20150328232A1 (zh)
EP (1) EP2925303A4 (zh)
JP (1) JP6357481B2 (zh)
KR (1) KR20150089087A (zh)
CN (1) CN104822372A (zh)
AU (1) AU2013351934B2 (zh)
BR (1) BR112015012547A2 (zh)
CA (1) CA2890219A1 (zh)
HK (1) HK1216009A1 (zh)
IL (1) IL238984A0 (zh)
NZ (1) NZ707551A (zh)
WO (1) WO2014085813A1 (zh)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
JP6523247B2 (ja) 2013-03-15 2019-05-29 マンカインド コーポレイション 微結晶性ジケトピペラジン粒子の製造方法および乾燥粉末組成物の製造方法
EP3021834A1 (en) 2013-07-18 2016-05-25 MannKind Corporation Heat-stable dry powder pharmaceutical compositions and methods
PT3060041T (pt) 2013-10-25 2021-03-12 Insmed Inc Compostos de prostaciclina
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
JP6866043B2 (ja) 2014-11-18 2021-04-28 インスメッド インコーポレイテッド トレプロスチニルプロドラッグおよびトレプロスチニル誘導体プロドラッグの製造方法
WO2016176399A1 (en) * 2015-04-28 2016-11-03 Stc.Unm Compositions and methods for treatment of pulmonary hypertension
US20190231815A1 (en) * 2015-07-28 2019-08-01 Insmed Incorporated Compositions comprising copper chelators and methods of use thereof for treating vasculopathies
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. DRY POWDER OF TREPROSTINIL FOR THE TREATMENT OF PULMONARY HYPERTENSION
CN107811970B (zh) * 2016-09-12 2021-02-02 江苏艾立康药业股份有限公司 西里帕格多囊脂质体及其制备方法
CA3036307A1 (en) * 2016-09-15 2018-03-22 Camurus Ab Prostacyclin analogue formulations
KR102541885B1 (ko) 2016-09-26 2023-06-12 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드럭
JP7186385B2 (ja) * 2016-10-27 2022-12-09 国立大学法人大阪大学 疾患部位特異的リポソーム製剤
SG11202000593TA (en) 2017-07-24 2020-02-27 Pharmosa Biopharm Inc Liposome compositions comprising weak acid drugs and uses thereof
US20210113464A1 (en) * 2017-11-27 2021-04-22 Osaka University Disease-site-specific liposomal formulation
KR20230170124A (ko) 2018-05-07 2023-12-18 파모사 바이오팜 인코포레이티드 트레프로스티닐의 제어 방출을 위한 약제학적 조성물
JP7455144B2 (ja) 2019-04-29 2024-03-25 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
KR20210149157A (ko) * 2019-05-14 2021-12-08 파모사 바이오팜 인코포레이티드 약산성 약물의 약제학적 조성물 및 투여 방법
WO2021013861A1 (en) * 2019-07-22 2021-01-28 Nanomi, B.V. Sustained release trepostinil-compound microparticle compositions
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
JP2023523557A (ja) 2020-04-17 2023-06-06 ユナイテッド セラピューティクス コーポレイション 間質性肺疾患の治療における使用のためのトレプロスチニル
JP2023529828A (ja) 2020-06-09 2023-07-12 ユナイテッド セラピューティクス コーポレイション トレプロスチニルのフマリルジケトピペリジンプロドラッグ
KR20230134480A (ko) 2020-12-14 2023-09-21 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐 프로드러그로 질환을 치료하는 방법
AU2022310496A1 (en) * 2021-07-16 2024-02-15 Celator Pharmaceuticals, Inc. Methods for preparing liposomal formulations

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61289034A (ja) * 1985-06-17 1986-12-19 Teijin Ltd イソカルバサイクリン類脂肪乳剤
CA2091152C (en) * 1993-03-05 2005-05-03 Kirsten Westesen Solid lipid particles, particles of bioactive agents and methods for the manfuacture and use thereof
KR100591027B1 (ko) * 1997-12-26 2006-06-22 아스텔라스세이야쿠 가부시키가이샤 서방성 의약 조성물
JP2002521423A (ja) * 1998-07-31 2002-07-16 コリア インスティチュート オブ サイエンス アンド テクノロージ 遺伝子又は薬物運搬体としての脂質エマルジョン及び固形脂質微粒子
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US20050244503A1 (en) * 2003-05-19 2005-11-03 Rabinow Barrett E Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
ES2272914T3 (es) * 2003-05-20 2007-05-01 Ethypharm Composicion farmaceutica oral de liberacion sostenida.
CN100558351C (zh) * 2003-05-22 2009-11-11 联合治疗公司 化合物和释放前列环素类似物的方法
JP2008507585A (ja) * 2004-07-26 2008-03-13 コセリックス インク 微粒子製剤を用いて吸入したイロプロストによる肺高血圧症の治療
WO2007070851A2 (en) * 2005-12-15 2007-06-21 Acusphere, Inc. Processes for making particle-based pharmaceutical formulations for pulmonary or nasal administration
JP5797376B2 (ja) * 2006-05-15 2015-10-21 ユナイテッド セラピューティクス コーポレーション 定量吸入器を用いたトレプロスチニル投与
WO2008124639A2 (en) * 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Poly (amino acid) targeting moieties
EP2398443A2 (en) * 2009-02-20 2011-12-28 Micro Labs Limited Storage stable prostaglandin product
CN101669904B (zh) * 2009-09-29 2011-06-22 北京中海康医药科技发展有限公司 一种依前列醇脂质纳米粒及制备方法
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
JP5780775B2 (ja) * 2011-02-18 2015-09-16 株式会社Ｌｔｔバイオファーマ プロスタグランジンｉ２誘導体を含有するナノ粒子
WO2012124688A1 (ja) * 2011-03-14 2012-09-20 国立大学法人北海道大学 肺送達のためのベクター、導入剤及び使用

Also Published As

Publication number Publication date
JP6357481B2 (ja) 2018-07-11
EP2925303A4 (en) 2016-04-27
JP2016501233A (ja) 2016-01-18
NZ707551A (en) 2019-10-25
CN104822372A (zh) 2015-08-05
KR20150089087A (ko) 2015-08-04
AU2013351934A1 (en) 2015-05-21
US20150328232A1 (en) 2015-11-19
IL238984A0 (en) 2015-07-30
WO2014085813A1 (en) 2014-06-05
BR112015012547A2 (pt) 2017-07-11
AU2013351934B2 (en) 2018-03-29
CA2890219A1 (en) 2014-06-05
EP2925303A1 (en) 2015-10-07

Similar Documents

Publication Publication Date Title
HK1216009A1 (zh) 前列環素組合物及其使用方法
EP2836212A4 (en) NOVEL COMPOSITIONS AND METHOD
ZA201408594B (en) Xylitol-based anti-mucosal compositions and related methods and compositions
EP2935358A4 (en) DEPOSITS AND METHODS OF PREVENTING THEM AND METHOD OF USE THEREOF
HK1212625A1 (zh) 用於炎性疾病的抗- 、抗- 、抗- 、抗- 、抗- 和抗- 試劑
EP2806872A4 (en) BENDAMUSTIN COMPOSITIONS AND RELATED METHODS
HK1216250A1 (zh) '- '-羥基-二氫麥角胺化合物及組合物
HK1206970A1 (zh) 抗原組合物及方法
GB201200707D0 (en) Composition
SG2013076633A (en) Cleaning composition and cleaning method using the same
GB201315350D0 (en) Methods and compositions
HK1201270A1 (zh) 四唑- -基-和三唑- -基-芳基化合物及其作為除草劑的用途
GB201315347D0 (en) Methods and compositions
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
EP2878295A4 (en) COMPOSITION
EP2938391A4 (en) TRANSDERMAL BUPRENORPHINE COMPOSITIONS WITH DELAYED RELEASE AND METHOD OF USE THEREOF
EP2931280A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1
EP2852662A4 (en) HERPESVIRUS COMPOSITIONS AND RELATED METHODS
EP2837670A4 (en) COMPOSITION CONTAINING FLUOROBIPHENYL
GB201206035D0 (en) Composition
EP2910538A4 (en) AGENT COMPOSITION GENERATING GAS
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201209597D0 (en) Composition
GB201208133D0 (en) Composition
EP2834635A4 (en) COMPOSITIONS WITH A HEPARINE ACCUMULATIVE AND METHOD THEREFOR